Heat Biologics, Inc. (HTBX) Reaches New 1-Year Low at $0.46

Shares of Heat Biologics, Inc. (NASDAQ:HTBX) reached a new 52-week low during trading on Friday . The stock traded as low as $0.46 and last traded at $0.56, with a volume of 309900 shares trading hands. The stock had previously closed at $0.55.

Separately, Griffin Securities assumed coverage on Heat Biologics in a report on Tuesday, September 12th. They issued a “buy” rating and a $2.25 price target for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $2.13.

Heat Biologics (NASDAQ:HTBX) last issued its quarterly earnings data on Monday, November 13th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.03. The firm had revenue of $0.47 million during the quarter, compared to analysts’ expectations of $0.50 million. Heat Biologics had a negative return on equity of 140.93% and a negative net margin of 1,184.92%. sell-side analysts predict that Heat Biologics, Inc. will post -0.38 earnings per share for the current fiscal year.

An institutional investor recently raised its position in Heat Biologics stock. KCG Holdings Inc. increased its position in shares of Heat Biologics, Inc. (NASDAQ:HTBX) by 35.3% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 175,769 shares of the biopharmaceutical company’s stock after purchasing an additional 45,831 shares during the quarter. KCG Holdings Inc. owned 0.52% of Heat Biologics worth $156,000 as of its most recent filing with the SEC. 8.64% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://sportsperspectives.com/2017/11/19/heat-biologics-inc-htbx-reaches-new-1-year-low-at-0-46.html.

Heat Biologics Company Profile

Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).

Receive News & Ratings for Heat Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply